<DOC>
	<DOCNO>NCT02373813</DOCNO>
	<brief_summary>The purpose study evaluate efficacy etanercept monotherapy compare methotrexate monotherapy maintenance remission subject Rheumatoid Arthritis etanercept plus methotrexate therapy . This multicenter , randomize withdrawal , double-blind control study subject Rheumatoid Arthritis etanercept plus methotrexate therapy good disease control 6 month prior study entry . The study consist 30-day screening period , 24-week open label run-in period , 48-week double-blind treatment period 30-day safety follow-up period . Approximately 465 subject enrol approximately 325 subject randomly assign 2:2:1 ratio one three treatment group : etanercept 50 mg weekly subcutaneous injection plus oral placebo methotrexate ( n = 130 ) , oral methotrexate 10 25 mg weekly plus placebo etanercept ( n = 130 ) etanercept 50 mg weekly subcutaneous injection plus oral methotrexate 10 25 mg weekly ( n = 65 ) .</brief_summary>
	<brief_title>Study Etanercept Monotherapy v Methotrexate Monotherapy Maintenance Rheumatoid Arthritis Remission</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects must adults history moderate severe Rheumatoid Arthritis ; Subjects must good Rheumatoid Arthritis disease control ≥ 6 month remission define Simplified Disease Activity Index ≤ 3.3 screen end runin period . Subjects must etanercept 50 mg per week plus methotrexate therapy ≥ 6 month prior start runin period . The methotrexate dose must 10 25 mg per week ≥ 6 month prior start runin period dose must stable ≥ 8 week prior start runin period . Subject known history active tuberculosis , negative test tuberculosis screening . Subject use biologic disease modify antirheumatic drug etanercept OR use oral janus kinase inhibitor ≤ 6 month prior runin visit 1 Subject active infection ( include chronic localized infection ) antiinfectives indicate within 4 week prior runin visit 1 . Subject know alcohol addiction dependency use alcohol daily . Subject one significant concurrent medical condition per investigator judgment , include follow : poorly control diabetes chronic kidney disease stage IIIb , IV , V symptomatic heart failure ( New York Heart Association class II , III , IV ) myocardial infarction unstable angina pectoris within past 12 month prior randomization uncontrolled hypertension severe chronic pulmonary disease ( eg , require oxygen therapy ) multiple sclerosis demyelinate disease major chronic inflammatory disease connective tissue disease Rheumatoid Arthritis ( eg , systemic lupus erythematosus exception secondary Sjögren 's syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>